Achim Gass
Hat mitgewirkt an:
-
Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
-
Characterization of contrast-enhancing and non contrast-enhancing multiple sclerosis lesions with susceptibility-weighted imaging
-
Lesion probability mapping in MS patients using a regression network on MR fingerprinting
-
Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated...